Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Bramlage

Showing results (1-10 of 429) with videos related to

Pageof 43
Sort By:
Expert Opinion on Pharmacotherapy|June 23, 2009
Fixed-dose combinations of renin-angiotensin blocking agents with calcium channel blockers or hydrochlorothiazide in the treatment of hypertensionPeter Bramlage
Vascular Health and Risk Management|May 14, 2009
Fixed combination of irbesartan and hydrochlorothiazide in the management of hypertensionPeter Bramlage
Clinical Drug Investigation|April 14, 2010
Candesartan cilexetil/hydrochlorothiazide treatment in high-risk patients with type 2 diabetes mellitus and microalbuminuria: the CHILI T2D studyReinhard Ketelhut, Peter Bramlage
Perfusion|July 17, 2016
Early improvement of symptoms using LCZ696 in a patient with systolic heart failure and a reduced ejection fraction: a case reportJohannes Kohlmeier, Peter Bramlage
Expert Opinion on Pharmacotherapy|December 25, 2009
Differences in pharmacology and their translation into differences in clinical efficacy--a comparison of the renin angiotensin blocking agents irbesartan and losartanPeter Bramlage, Christoph Schindler
Current Diabetes Reports|February 12, 2013
Insulin use early in the course of type 2 diabetes mellitus: the ORIGIN trialMarkolf Hanefeld, Peter Bramlage
Expert Opinion on Pharmacotherapy|May 20, 2014
Vildagliptin , a DPP-4 inhibitor for the twice-daily treatment of type 2 diabetes mellitus with or without metforminThomas Forst, Peter Bramlage
The Heart Surgery Forum|January 4, 2019
Use of the ClearSight® System for Continuous Noninvasive Hemodynamic Monitoring during Heart Valve Interventions: Review of the Literature and Single-Site ExperienceGeorge Gellert, Peter Bramlage
Hypertension Research : Official Journal of the Japanese Society of Hypertension|November 5, 2010
Going beyond the optimization of pharmacotherapyLionel Thevathasan, Peter Bramlage
Cardiovascular Diabetology|March 31, 2009
Blood pressure reduction, persistence and costs in the evaluation of antihypertensive drug treatment--a reviewPeter Bramlage, Joerg Hasford
Pageof 43

Showing results (1-10 of 429) with videos related to

Sort By:
Pageof 43
Expert Opinion on Pharmacotherapy|June 23, 2009
Fixed-dose combinations of renin-angiotensin blocking agents with calcium channel blockers or hydrochlorothiazide in the treatment of hypertensionPeter Bramlage
Vascular Health and Risk Management|May 14, 2009
Fixed combination of irbesartan and hydrochlorothiazide in the management of hypertensionPeter Bramlage
Clinical Drug Investigation|April 14, 2010
Candesartan cilexetil/hydrochlorothiazide treatment in high-risk patients with type 2 diabetes mellitus and microalbuminuria: the CHILI T2D studyReinhard Ketelhut, Peter Bramlage
Perfusion|July 17, 2016
Early improvement of symptoms using LCZ696 in a patient with systolic heart failure and a reduced ejection fraction: a case reportJohannes Kohlmeier, Peter Bramlage
Expert Opinion on Pharmacotherapy|December 25, 2009
Differences in pharmacology and their translation into differences in clinical efficacy--a comparison of the renin angiotensin blocking agents irbesartan and losartanPeter Bramlage, Christoph Schindler
Current Diabetes Reports|February 12, 2013
Insulin use early in the course of type 2 diabetes mellitus: the ORIGIN trialMarkolf Hanefeld, Peter Bramlage
Expert Opinion on Pharmacotherapy|May 20, 2014
Vildagliptin , a DPP-4 inhibitor for the twice-daily treatment of type 2 diabetes mellitus with or without metforminThomas Forst, Peter Bramlage
The Heart Surgery Forum|January 4, 2019
Use of the ClearSight® System for Continuous Noninvasive Hemodynamic Monitoring during Heart Valve Interventions: Review of the Literature and Single-Site ExperienceGeorge Gellert, Peter Bramlage
Hypertension Research : Official Journal of the Japanese Society of Hypertension|November 5, 2010
Going beyond the optimization of pharmacotherapyLionel Thevathasan, Peter Bramlage
Cardiovascular Diabetology|March 31, 2009
Blood pressure reduction, persistence and costs in the evaluation of antihypertensive drug treatment--a reviewPeter Bramlage, Joerg Hasford
Pageof 43